The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026. On May 14, Piper Sandler lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to ...

Kissei Pharmaceutical Co., which sells Amgen Inc.’s drug Tavneos in Japan, is recommending that doctors stop prescribing it, ...

May 19 (Reuters) - Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich taking over the role in September. Dittrich, who previously held senior finance ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Amgen (AMGN) stock is in focus as partner Kissei (KSPHF) reports 20 deaths linked to the U.S. company's rare disease drug.

About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with Amgen's rare disease ...

The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating five clinical trials in the process. The Big Pharma has scrapped AMG 329, ...

Amgen’s (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in ...